The Global Flowable Hemostats Market was valued at USD 1.08 billion in 2025 and is estimated to grow at a CAGR of 5.8% to reach USD 1.89 billion by 2035.
The market is experiencing notable growth due to the rising number of surgical procedures being performed worldwide, along with the increasing prevalence of trauma injuries and chronic health conditions that require effective bleeding management during surgeries. Flowable hemostats have become an important component in modern surgical practices because they are specifically designed to control bleeding in situations where traditional methods may not provide sufficient results. These products are increasingly utilized across multiple surgical specialties due to their fast clotting performance, ease of application, and ability to adapt to complex surgical environments. Growing demand for minimally invasive surgical procedures is further contributing to market expansion, as surgeons increasingly require advanced hemostatic solutions that support precision, efficiency, and improved patient outcomes. In addition, healthcare providers are placing greater emphasis on perioperative blood management and surgical safety, which continues to strengthen adoption of flowable hemostatic products across hospitals and specialty care facilities globally.
The market is also benefiting from the growing surgical burden associated with aging populations and increasing rates of emergency hospital admissions worldwide. Rising awareness regarding advanced surgical bleeding control solutions and the expanding use of minimally invasive procedures are further supporting industry growth. Following the disruption caused by the COVID-19 pandemic, hospitals and healthcare systems resumed a large volume of delayed and elective surgical procedures, which significantly accelerated demand for flowable hemostats. Continuous investments in product development, regulatory approvals, and geographic expansion initiatives by leading biotechnology and medical device companies are also contributing to market advancement. Manufacturers are increasingly focusing on improving product performance, ease of use, and clinical compatibility to address the evolving needs of surgeons and healthcare providers across diverse medical specialties.
The gelatin-based flowable hemostats segment generated USD 678 million in 2025. This category includes products derived from porcine and bovine sources and continues to maintain strong market demand because of its proven clinical effectiveness and broad surgical applicability. Gelatin-based flowable hemostats are widely preferred in healthcare settings due to their ability to provide fast and dependable bleeding control, especially in challenging surgical areas and irregular wound surfaces. Their adaptability and effectiveness across various surgical procedures continue to support widespread adoption in hospitals and surgical centers.
The hospitals and clinics segment accounted for USD 827.2 million in 2025 and is projected to grow at a CAGR of 5.7% throughout 2035. Hospitals and clinics remain the primary end-use settings for flowable hemostats because these facilities perform a high volume of both routine and complex surgical procedures. The increasing incidence of chronic diseases, combined with rising global demand for surgical interventions, is driving the adoption of advanced hemostatic solutions within healthcare institutions. Growing emphasis on improving surgical outcomes, reducing blood loss, and enhancing patient recovery is also contributing to strong demand for flowable hemostats across hospitals and clinical environments.
North America Flowable Hemostats Market held a 40.4% in 2025. The region continues to maintain a leading position due to the high number of surgical procedures performed annually, strong adoption of advanced surgical technologies, and increasing focus on effective perioperative blood management strategies across healthcare systems. The United States remains a major contributor to regional growth, supported by advanced healthcare infrastructure, growing surgical volumes, and increasing utilization of innovative hemostatic products across medical facilities.
Major companies operating in the Global Flowable Hemostats Market include Baxter International, Ethicon (Johnson & Johnson), Teleflex Incorporated, Integra LifeSciences Holdings Corporation, Pfizer, Becton Dickinson and Company (BD), Medcura, Aegis Lifesciences, Ferrosan Medical Devices, Dalim Tissen, and 3-D Matrix. Companies in the flowable hemostats market are focusing on product innovation, strategic partnerships, and geographic expansion to strengthen their competitive position. Leading manufacturers are investing heavily in research and development to introduce advanced hemostatic products with improved clotting efficiency, enhanced biocompatibility, and broader surgical applications. Many players are expanding their global footprint through collaborations with hospitals, healthcare providers, and distribution networks to improve product accessibility across emerging and developed markets. Regulatory approvals and clinical validation studies remain key priorities for companies aiming to strengthen physician confidence and increase product adoption. Businesses are also emphasizing minimally invasive surgical applications and customized hemostatic solutions to meet evolving healthcare requirements. In addition, mergers, acquisitions, and investments in manufacturing capabilities are helping companies improve supply chain efficiency and reinforce their long-term market presence.
This product will be delivered within 2-4 business days.
The market is experiencing notable growth due to the rising number of surgical procedures being performed worldwide, along with the increasing prevalence of trauma injuries and chronic health conditions that require effective bleeding management during surgeries. Flowable hemostats have become an important component in modern surgical practices because they are specifically designed to control bleeding in situations where traditional methods may not provide sufficient results. These products are increasingly utilized across multiple surgical specialties due to their fast clotting performance, ease of application, and ability to adapt to complex surgical environments. Growing demand for minimally invasive surgical procedures is further contributing to market expansion, as surgeons increasingly require advanced hemostatic solutions that support precision, efficiency, and improved patient outcomes. In addition, healthcare providers are placing greater emphasis on perioperative blood management and surgical safety, which continues to strengthen adoption of flowable hemostatic products across hospitals and specialty care facilities globally.
The market is also benefiting from the growing surgical burden associated with aging populations and increasing rates of emergency hospital admissions worldwide. Rising awareness regarding advanced surgical bleeding control solutions and the expanding use of minimally invasive procedures are further supporting industry growth. Following the disruption caused by the COVID-19 pandemic, hospitals and healthcare systems resumed a large volume of delayed and elective surgical procedures, which significantly accelerated demand for flowable hemostats. Continuous investments in product development, regulatory approvals, and geographic expansion initiatives by leading biotechnology and medical device companies are also contributing to market advancement. Manufacturers are increasingly focusing on improving product performance, ease of use, and clinical compatibility to address the evolving needs of surgeons and healthcare providers across diverse medical specialties.
The gelatin-based flowable hemostats segment generated USD 678 million in 2025. This category includes products derived from porcine and bovine sources and continues to maintain strong market demand because of its proven clinical effectiveness and broad surgical applicability. Gelatin-based flowable hemostats are widely preferred in healthcare settings due to their ability to provide fast and dependable bleeding control, especially in challenging surgical areas and irregular wound surfaces. Their adaptability and effectiveness across various surgical procedures continue to support widespread adoption in hospitals and surgical centers.
The hospitals and clinics segment accounted for USD 827.2 million in 2025 and is projected to grow at a CAGR of 5.7% throughout 2035. Hospitals and clinics remain the primary end-use settings for flowable hemostats because these facilities perform a high volume of both routine and complex surgical procedures. The increasing incidence of chronic diseases, combined with rising global demand for surgical interventions, is driving the adoption of advanced hemostatic solutions within healthcare institutions. Growing emphasis on improving surgical outcomes, reducing blood loss, and enhancing patient recovery is also contributing to strong demand for flowable hemostats across hospitals and clinical environments.
North America Flowable Hemostats Market held a 40.4% in 2025. The region continues to maintain a leading position due to the high number of surgical procedures performed annually, strong adoption of advanced surgical technologies, and increasing focus on effective perioperative blood management strategies across healthcare systems. The United States remains a major contributor to regional growth, supported by advanced healthcare infrastructure, growing surgical volumes, and increasing utilization of innovative hemostatic products across medical facilities.
Major companies operating in the Global Flowable Hemostats Market include Baxter International, Ethicon (Johnson & Johnson), Teleflex Incorporated, Integra LifeSciences Holdings Corporation, Pfizer, Becton Dickinson and Company (BD), Medcura, Aegis Lifesciences, Ferrosan Medical Devices, Dalim Tissen, and 3-D Matrix. Companies in the flowable hemostats market are focusing on product innovation, strategic partnerships, and geographic expansion to strengthen their competitive position. Leading manufacturers are investing heavily in research and development to introduce advanced hemostatic products with improved clotting efficiency, enhanced biocompatibility, and broader surgical applications. Many players are expanding their global footprint through collaborations with hospitals, healthcare providers, and distribution networks to improve product accessibility across emerging and developed markets. Regulatory approvals and clinical validation studies remain key priorities for companies aiming to strengthen physician confidence and increase product adoption. Businesses are also emphasizing minimally invasive surgical applications and customized hemostatic solutions to meet evolving healthcare requirements. In addition, mergers, acquisitions, and investments in manufacturing capabilities are helping companies improve supply chain efficiency and reinforce their long-term market presence.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Product Type, 2022-2035 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Application, 2022-2035 ($ Mn)
Chapter 7 Market Estimates and Forecast, by End Use, 2022-2035 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
Chapter 9 Company Profiles
Companies Mentioned
The companies profiled in this Flowable Hemostats market report include:- Aegis Lifesciences
- Baxter International
- Becton Dickinson and Company (BD)
- Dalim Tissen
- Ethicon (Johnson & Johnson)
- Ferrosan Medical Devices
- Integra LifeSciences Holdings Corporation
- Medcura
- Pfizer
- Teleflex Incorporated
- 3-D Matrix
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 126 |
| Published | May 2026 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 1.08 Billion |
| Forecasted Market Value ( USD | $ 1.89 Billion |
| Compound Annual Growth Rate | 5.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
